Listed

BridgeBio Pharma, Inc.: Form 10-Q for the period ended Mar 31, 2020

Filed with the SEC on May 14, 2020 and accepted by EDGAR at May 13, 2020, 19:34 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2020-01-01 to 2020-03-31$68.2mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2020-01-01 to 2020-03-31−$102.5mus-gaap:OperatingIncomeLoss
Interest expense3 months2020-01-01 to 2020-03-31$4.0mus-gaap:InterestExpense
Net income3 months2020-01-01 to 2020-03-31−$104.1mus-gaap:ProfitLoss
Diluted EPS3 months2020-01-01 to 2020-03-31−$0.78us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow3 months2020-01-01 to 2020-03-31−$83.9mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2020-01-01 to 2020-03-31$4.5mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases3 months2020-01-01 to 2020-03-31$75.0mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2020-03-31$757.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2020-03-31$925.0mus-gaap:AssetsCurrent
Total assetsAt period end2020-03-31$989.8mus-gaap:Assets
Current liabilitiesAt period end2020-03-31$64.9mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2020-03-31$537.7mus-gaap:Liabilities
Long-term debtAt period end2020-03-31$92.4mus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2020-03-31$380.7mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001564590-20-025197. Last ingested by Listed: Nov 12, 2026, 17:56 ET. Listed shows no prices and gives no investment advice.